CY1111963T1 - Ανταγωνιστικα αντισωματα il-17 - Google Patents

Ανταγωνιστικα αντισωματα il-17

Info

Publication number
CY1111963T1
CY1111963T1 CY20111100936T CY111100936T CY1111963T1 CY 1111963 T1 CY1111963 T1 CY 1111963T1 CY 20111100936 T CY20111100936 T CY 20111100936T CY 111100936 T CY111100936 T CY 111100936T CY 1111963 T1 CY1111963 T1 CY 1111963T1
Authority
CY
Cyprus
Prior art keywords
competitive antibodies
antibody
human
disease
heavy
Prior art date
Application number
CY20111100936T
Other languages
Greek (el)
English (en)
Inventor
Padova Franco E Di
Hermann Gram
Hans Hofstetter
Margit Jeschke
Jean-Michel Rondeau
Den Berg Wim Van
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32982602&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1111963(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CY1111963T1 publication Critical patent/CY1111963T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CY20111100936T 2004-08-05 2011-09-27 Ανταγωνιστικα αντισωματα il-17 CY1111963T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0417487.6A GB0417487D0 (en) 2004-08-05 2004-08-05 Organic compound
EP05770286.2A EP1776142B9 (en) 2004-08-05 2005-08-04 Il-17 antagonistic antibodies

Publications (1)

Publication Number Publication Date
CY1111963T1 true CY1111963T1 (el) 2015-11-04

Family

ID=32982602

Family Applications (6)

Application Number Title Priority Date Filing Date
CY20111100936T CY1111963T1 (el) 2004-08-05 2011-09-27 Ανταγωνιστικα αντισωματα il-17
CY20141100628T CY1115444T1 (el) 2004-08-05 2014-08-08 Ανταγωνιστικα αντισωματα il-17
CY20151100401T CY1116256T1 (el) 2004-08-05 2015-05-07 Il-17 ανταγωνιστικα αντισωματα
CY2015030C CY2015030I2 (el) 2004-08-05 2015-07-10 Ανταγωνιστικα αντισωματα il-17
CY181100727T CY1120723T1 (el) 2004-08-05 2018-07-11 Ανταγωνιστικα αντισωματα il-17
CY2018027C CY2018027I1 (el) 2004-08-05 2018-10-10 Ανταγωνιστικα αντισωματα il-17

Family Applications After (5)

Application Number Title Priority Date Filing Date
CY20141100628T CY1115444T1 (el) 2004-08-05 2014-08-08 Ανταγωνιστικα αντισωματα il-17
CY20151100401T CY1116256T1 (el) 2004-08-05 2015-05-07 Il-17 ανταγωνιστικα αντισωματα
CY2015030C CY2015030I2 (el) 2004-08-05 2015-07-10 Ανταγωνιστικα αντισωματα il-17
CY181100727T CY1120723T1 (el) 2004-08-05 2018-07-11 Ανταγωνιστικα αντισωματα il-17
CY2018027C CY2018027I1 (el) 2004-08-05 2018-10-10 Ανταγωνιστικα αντισωματα il-17

Country Status (40)

Country Link
US (9) US7807155B2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
EP (5) EP2364729B3 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
JP (1) JP4682200B2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
KR (2) KR100852523B1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
CN (1) CN101001645B (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
AR (1) AR050200A1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
AT (1) ATE517924T1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
AU (2) AU2005268857C1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
BE (1) BE2015C041I2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
BR (3) BR122017009404B1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
CA (1) CA2573586C (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
CY (6) CY1111963T1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
DK (4) DK2366405T3 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
EC (1) ECSP077198A (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
ES (4) ES2487533T7 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
FR (1) FR15C0048I2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
GB (1) GB0417487D0 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
HK (1) HK1256639A1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
HR (3) HRP20110758T4 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
HU (4) HUE025815T2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
IL (1) IL180717A (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
LT (3) LT2902039T (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
LU (2) LU92768I2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
MA (1) MA28982B1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
MX (1) MX2007001338A (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
MY (1) MY144925A (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
NL (1) NL300749I2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
NO (9) NO336279B1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
NZ (1) NZ552658A (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
PE (1) PE20060418A1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
PL (4) PL1776142T4 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
PT (4) PT2366405E (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
RU (2) RU2426741C3 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
SG (1) SG155186A1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
SI (4) SI2902039T1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
TN (1) TNSN07034A1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
TR (1) TR201808057T4 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
TW (1) TWI359153B (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
WO (1) WO2006013107A1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
ZA (1) ZA200700242B (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)

Families Citing this family (157)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
GB0417487D0 (en) * 2004-08-05 2004-09-08 Novartis Ag Organic compound
GB0425569D0 (en) 2004-11-19 2004-12-22 Celltech R&D Ltd Biological products
ATE445415T1 (de) * 2005-09-01 2009-10-15 Schering Corp Verwendung von il-23 und il-17-antagonisten zur behandlung von autoimmuner entzündlicher augenerkrankung
EP3366702B1 (en) 2005-12-13 2023-08-09 Eli Lilly And Company Anti-il-17 antibodies
HUE039865T2 (hu) 2005-12-20 2019-02-28 Sbi Biotech Co Ltd Anti-ILT7 antitest
AR060017A1 (es) 2006-01-13 2008-05-21 Novartis Ag Composiciones y metodos de uso para anticuerpos de dickkopf -1
RU2430110C2 (ru) * 2006-01-31 2011-09-27 Новартис Аг Антитела - антагонисты интерлейкина-17 (ил-17) для лечения рака
US7910703B2 (en) 2006-03-10 2011-03-22 Zymogenetics, Inc. Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
CA2655372A1 (en) 2006-06-13 2007-12-21 Zymogenetics, Inc. Il-17 and il-23 antagonists and methods of using the same
TW200815469A (en) * 2006-06-23 2008-04-01 Astrazeneca Ab Compounds
GB0612928D0 (en) * 2006-06-29 2006-08-09 Ucb Sa Biological products
KR101218484B1 (ko) 2006-08-11 2013-01-04 머크 샤프 앤드 돔 코포레이션 Ｉｌ-17ａ에 대한 항체
GB0620729D0 (en) 2006-10-18 2006-11-29 Ucb Sa Biological products
TWI426918B (zh) 2007-02-12 2014-02-21 Merck Sharp & Dohme Ｉｌ-２３拮抗劑於治療感染之用途
MX2009009167A (es) 2007-02-28 2009-09-04 Schering Corp Terapia de combinacion para el tratamiento de trastornos inmunes.
EP4177268A3 (en) 2007-05-29 2023-05-24 Novartis AG New indications for anti-il-1beta therapy
AU2008266745B2 (en) * 2007-06-20 2014-04-17 Merck Sharp & Dohme Corp. Joint destruction biomarkers for anti-IL-17A therapy of inflammatory joint disease
WO2009015063A2 (en) * 2007-07-23 2009-01-29 Centocor Methods and compositions for treating fibrosis related disorders using il-17 antagonists
US20110195509A1 (en) * 2007-09-06 2011-08-11 Drew Pardoll Treatment of th17-mediated autoimmune disease via inhibition of stat 3
WO2009072802A2 (en) * 2007-12-03 2009-06-11 Amorepacific Corporation Composition for slimming
WO2009082624A2 (en) * 2007-12-10 2009-07-02 Zymogenetics, Inc. Antagonists of il-17a, il-17f, and il-23 and methods of using the same
US9309313B2 (en) 2008-01-09 2016-04-12 The Schepens Eye Research Institute, Inc. Therapeutic compositions for treatment of ocular inflammatory disorders
GB0807413D0 (en) 2008-04-23 2008-05-28 Ucb Pharma Sa Biological products
US9353180B2 (en) * 2008-04-29 2016-05-31 Amgen Research (Munich) Gmbh Method of treatment by the administration of inhibitors of GM-CSF and IL-17
MX2010011955A (es) 2008-04-29 2011-01-21 Abbott Lab Inmunoglobulinas de dominio variable doble y usos de las mismas.
CN104628855A (zh) 2008-05-05 2015-05-20 诺维莫尼公司 抗il-17a/il-17f交叉反应性抗体及其使用方法
SG191625A1 (en) 2008-06-03 2013-07-31 Abbott Lab Dual variable domain immunoglobulins and uses thereof
AR072001A1 (es) 2008-06-03 2010-07-28 Abbott Lab Inmunoglobulina con dominio variable dual y usos de la misma
EP2321422A4 (en) 2008-07-08 2013-06-19 Abbvie Inc PROSTAGLANDINE E2 VARIABLE DOUBLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF
CA2737636A1 (en) * 2008-09-29 2010-04-01 Roche Glycart Ag Antibodies against human il17 and uses thereof
UY32477A (es) 2009-03-05 2010-06-30 Abbott Lab Proteínas de unión a il-17
RS56661B1 (sr) * 2009-04-27 2018-03-30 Novartis Ag Kompozicije i postupci za povećanje rasta mišića
CN104974250A (zh) 2009-05-05 2015-10-14 诺维莫尼公司 抗il-17f抗体及其使用方法
BR112012004710A2 (pt) 2009-09-01 2016-08-16 Abbott Lab imunoglobulinas de domínio variável duplo e uso das mesmas
US20130064788A1 (en) * 2009-10-10 2013-03-14 Eleven Biotherapeutics, Inc. Il-17 family cytokine compositions and uses
BR112012008833A2 (pt) 2009-10-15 2015-09-08 Abbott Lab imunoglobulinas de dominio variavel duplo e usos das mesmas
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
CA2779257C (en) 2009-10-30 2019-03-12 Janssen Biotech, Inc. Il-17a antagonists
CN102906118B (zh) 2010-05-20 2017-07-28 埃博灵克斯股份有限公司 与her3相关的生物材料
JP2013537415A (ja) 2010-08-03 2013-10-03 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリンおよびその使用
WO2012018767A2 (en) 2010-08-05 2012-02-09 Anaptysbio, Inc. Antibodies directed against il-17
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
AU2011293253B2 (en) 2010-08-26 2014-12-11 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
CA2821992A1 (en) 2010-10-01 2012-04-05 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
BR112013008501A2 (pt) * 2010-10-08 2016-08-16 Novartis Ag métodos para o tratamento de psoríase usando anatgonistas de il-17
CA3116725C (en) * 2010-11-05 2023-10-24 Novartis Ag Secukinumab for use in the treatment of psoriatic arthritis
AU2014259526B2 (en) * 2010-11-05 2016-02-04 Novartis Ag Methods of treating ankylosing spondylitis using IL-17 antagonists
AR084234A1 (es) 2010-12-13 2013-05-02 Novartis Ag Metodos predictivos y metodos para tratar artritis usando antagonistas de interleuquina 17 (il-17)
JP5947041B2 (ja) * 2011-01-07 2016-07-06 第一三共ヘルスケア株式会社 安全なｉｌ−１７産生抑制剤
US10208349B2 (en) 2011-01-07 2019-02-19 Ucb Biopharma Sprl Lipocalin 2 as a biomarker for IL-17 inhibitor therapy efficacy
GB201100282D0 (en) 2011-01-07 2011-02-23 Ucb Pharma Sa Biological methods
EP2663869A1 (en) * 2011-01-13 2013-11-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and kits for predicting the risk of having a cardiovascular event in a subject
WO2012095662A1 (en) 2011-01-14 2012-07-19 Ucb Pharma S.A. Antibody molecules which bind il-17a and il-17f
WO2012125680A1 (en) 2011-03-16 2012-09-20 Novartis Ag Methods of treating vasculitis using an il-17 binding molecule
US9624261B2 (en) 2011-03-29 2017-04-18 Glaxosmithkline Llc Buffer system for protein purification
WO2012135805A2 (en) 2011-03-31 2012-10-04 modeRNA Therapeutics Delivery and formulation of engineered nucleic acids
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
DK3682905T3 (da) 2011-10-03 2022-02-28 Modernatx Inc Modificerede nukleosider, nukleotider og nukleinsyrer og anvendelser deraf
KR20140097178A (ko) * 2011-11-21 2014-08-06 노파르티스 아게 IL-17 길항제 및 건선성 관절염 (PsA) 반응 또는 비-반응 대립유전자를 이용하여 PsA를 치료하는 방법
WO2013082282A1 (en) 2011-12-02 2013-06-06 lNOVARTIS AG Anti-il-1beta (interleukin-1beta) antibody-based prophylactic therapy to prevent complications leading to vaso-occlusion in sickle cell disease.
EP2791172B1 (en) 2011-12-16 2017-07-19 Synthon Biopharmaceuticals B.V. Compounds and methods for treating inflammatory diseases
KR20140102759A (ko) 2011-12-16 2014-08-22 모더나 세라퓨틱스, 인코포레이티드 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물
TW201333035A (zh) 2011-12-30 2013-08-16 Abbvie Inc 針對ｉｌ－１３及／或ｉｌ－１７之雙特異性結合蛋白
US9284283B2 (en) 2012-02-02 2016-03-15 Ensemble Therapeutics Corporation Macrocyclic compounds for modulating IL-17
WO2013151672A2 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of oncology-related proteins and peptides
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
EP2834273B1 (en) 2012-04-05 2018-08-22 F.Hoffmann-La Roche Ag Bispecific antibodies against human tweak and human il17 and uses thereof
US20150125462A1 (en) 2012-04-20 2015-05-07 Stephan Bek Methods of treating ankylosing spondylitis using il-17 antagonists
JP6362587B2 (ja) 2012-05-22 2018-07-25 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｉｌ−１７ａ／ｆｉｌ−２３二重特異性抗体およびその使用
AR093297A1 (es) 2012-10-31 2015-05-27 Amgen Res (Munich) Gmbh Formulacion liquida que comprende un compuesto neutralizante de gm-csf
US9833410B2 (en) 2012-10-31 2017-12-05 Takeda Gmbh Lyophilized formulation comprising GM-CSF neutralizing compound
SG11201503412RA (en) 2012-11-01 2015-05-28 Abbvie Inc Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof
LT2922554T (lt) 2012-11-26 2022-06-27 Modernatx, Inc. Terminaliai modifikuota rnr
WO2014107737A2 (en) 2013-01-07 2014-07-10 Eleven Biotherapeutics, Inc. Local delivery of il-17 inhibitors for treating ocular disease
US9193788B2 (en) 2013-02-08 2015-11-24 Novartis Ag Anti-IL-17A antibodies and their uses
EP2970459A2 (en) 2013-03-15 2016-01-20 AbbVie Inc. Dual specific binding proteins directed against il-1beta and il-17
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
WO2014155278A2 (en) * 2013-03-26 2014-10-02 Novartis Ag Methods of treating autoimmune diseases using il-17 antagonists
WO2014161570A1 (en) 2013-04-03 2014-10-09 Roche Glycart Ag Antibodies against human il17 and uses thereof
US9707154B2 (en) 2013-04-24 2017-07-18 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9603882B2 (en) 2013-08-13 2017-03-28 Industrial Technology Research Institute Method for modulating Th17 cells and method for treating a disease related to modulation of Th17 cells
WO2015022656A1 (en) 2013-08-15 2015-02-19 Novartis Ag Methods of treating generalized pustular psoriasis (gpp) using il-17 antagonists
KR20240090993A (ko) 2013-08-30 2024-06-21 다케다 야쿠힌 고교 가부시키가이샤 류마티스성 관절염의 치료에서 또는 진통제로서 사용하기 위한 gm-csf 중화 항체
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
SG11201602503TA (en) 2013-10-03 2016-04-28 Moderna Therapeutics Inc Polynucleotides encoding low density lipoprotein receptor
EP3072905B1 (en) * 2013-11-18 2020-08-19 Shanghai Hengrui Pharmaceutical Co., Ltd. Il-17a binding agent and uses thereof
JP2017508446A (ja) * 2014-01-28 2017-03-30 北京韓美薬品有限公司 二機能性融合タンパク質及びその製造方法並びに使用
TWI713453B (zh) 2014-06-23 2020-12-21 美商健生生物科技公司 干擾素α及ω抗體拮抗劑
HUE067081T2 (hu) * 2014-09-10 2024-09-28 Novartis Ag Il-17 antagonisták alkalmazása strukturális károsodás progressziójának gátlására arthritis psoriaticában szenvedõ betegekben
RU2609627C2 (ru) * 2014-09-26 2017-02-02 Закрытое Акционерное Общество "Биокад" Высокоаффинные и агрегационно стабильные антитела на основе вариабельных доменов vl и производного vhh
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
ES2952717T3 (es) 2014-10-14 2023-11-03 Novartis Ag Moléculas de anticuerpos contra PD-L1 y usos de las mismas
WO2016094881A2 (en) 2014-12-11 2016-06-16 Abbvie Inc. Lrp-8 binding proteins
AR103172A1 (es) * 2014-12-22 2017-04-19 Novartis Ag Reducción selectiva de residuos de cisteina en anticuerpos il-17
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
DK3245224T3 (da) 2015-01-12 2020-09-21 Affibody Ab Il-17a-bindende polypeptider
CN107407677B (zh) 2015-01-28 2020-07-17 豪夫迈·罗氏有限公司 多发性硬化的基因表达标志和治疗
CN105315371B (zh) 2015-03-05 2018-05-29 北京百特美博生物科技有限公司 抗人il-17单克隆抗体
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
KR20180017145A (ko) 2015-07-16 2018-02-20 일라이 릴리 앤드 캄파니 소양증의 치료
EP3317301B1 (en) 2015-07-29 2021-04-07 Novartis AG Combination therapies comprising antibody molecules to lag-3
WO2017019896A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to pd-1
WO2017019897A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to tim-3
WO2017068472A1 (en) 2015-10-19 2017-04-27 Novartis Ag Methods of treating non-radiographic axial spondyloarthritis using interleukin-17 (il-17) antagonists
JP2019503349A (ja) 2015-12-17 2019-02-07 ノバルティス アーゲー Ｐｄ−１に対する抗体分子およびその使用
KR102457751B1 (ko) 2016-03-10 2022-10-21 악셀레론 파마 인코포레이티드 액티빈 타입 2 수용체 결합 단백질 및 이의 용도
JP6979976B2 (ja) 2016-03-10 2021-12-15 ヴィエラ バイオ，インコーポレーテッド Ｉｌｔ７結合分子及びその使用方法
RU2680011C2 (ru) 2016-04-29 2019-02-14 Закрытое Акционерное Общество "Биокад" Триспецифические антитела против il-17a, il-17f и другой провоспалительной молекулы
FR3051673B1 (fr) * 2016-05-24 2018-06-22 Assistance Publique - Hopitaux De Paris Inhibiteurs de la voie de l'interleukine 17 pour le traitement des infections chroniques dues a hpv
CN107488227A (zh) * 2016-06-12 2017-12-19 三生国健药业（上海）股份有限公司 抗人白细胞介素‑17a单克隆抗体、其制备方法和应用
WO2017221174A1 (en) 2016-06-22 2017-12-28 Novartis Ag Methods of treating vitiligo using interleukin-17 (il-17) antibodies
EP3487881B1 (en) 2016-07-19 2024-08-21 Novartis AG Methods of treating new-onset plaque type psoriasis using il-17 antagonists
BR112019004990A2 (pt) 2016-09-14 2019-06-04 Beijing hanmi pharm co ltd anticorpo que se liga especificamente a il-17a e fragmento funcional do mesmo
JP2019505516A (ja) 2016-11-28 2019-02-28 ノバルティス アーゲー インターロイキン−１７（ｉｌ−１７）アンタゴニストを使用してざ瘡を治療する方法
UA126574C2 (uk) 2017-02-10 2022-11-02 Дженентек, Інк. Антитіло проти триптази, його композиція та застосування
WO2018158741A1 (en) 2017-03-03 2018-09-07 Novartis Ag Psoriasis disease modification following long-term treatment with an il-17 antagonist
TW201842933A (zh) 2017-05-05 2018-12-16 瑞士商諾華公司 使用il-17拮抗劑選擇性治療氣喘的方法
CN108359011B (zh) 2017-07-21 2019-06-25 华博生物医药技术（上海）有限公司 靶向于白介素17a的抗体、其制备方法和应用
WO2019087133A1 (en) 2017-11-02 2019-05-09 Novartis Ag Method of treating tendinopathy using interleukin-17 (il-17)
US20200277369A1 (en) 2017-11-20 2020-09-03 Novartis Ag Method of treating hidradentitis suppurativa with il-17 antagonists
KR20200096253A (ko) 2017-11-30 2020-08-11 노파르티스 아게 Bcma-표적화 키메라 항원 수용체, 및 이의 용도
EP3773717A4 (en) * 2018-03-29 2022-05-11 REMD Biotherapeutics, Inc. TREATMENT OF AUTOIMMUNE AND INFLAMMATION DISEASES WITH ANTIBODIES THAT BIND INTERLEUKIN-17A (IL-17A).
US11492409B2 (en) 2018-06-01 2022-11-08 Novartis Ag Binding molecules against BCMA and uses thereof
US12134644B2 (en) 2018-07-31 2024-11-05 Weiqun SHEN Anti-IL-17A antibodies and use thereof
EP3856772A1 (en) 2018-09-25 2021-08-04 Institut National de la Santé et de la Recherche Médicale (INSERM) Use of antagonists of th17 cytokines for the treatment of bronchial remodeling in patients suffering from allergic asthma
EP3689907A1 (en) 2019-01-31 2020-08-05 Numab Therapeutics AG Antibodies targeting il-17a and methods of use thereof
SG11202107995SA (en) 2019-01-31 2021-08-30 Numab Therapeutics AG Multispecific antibodies having specificity for tnfa and il-17a, antibodies targeting il-17a, and methods of use thereof
SG11202108627SA (en) 2019-02-18 2021-09-29 Lilly Co Eli Therapeutic antibody formulation
CN110179746A (zh) * 2019-05-17 2019-08-30 通化东宝生物科技有限公司 一种稳定的苏金单抗注射剂及其制备方法
AU2020284114B2 (en) 2019-05-31 2025-06-26 Fibrobiologics, Inc. Concurrent activation of regenerative and tolerogenic processes by fibroblast-based compositions for the treatment of multiple sclerosis
CN110343666B (zh) * 2019-07-10 2023-05-30 通化东宝药业股份有限公司 一种cho细胞培养的补料培养基及其制备方法和应用
CN114286827B (zh) 2019-07-26 2024-01-12 神州细胞工程有限公司 人源化抗il17a抗体及其应用
US20220267432A1 (en) 2019-07-30 2022-08-25 Jiangsu Hengrui Medicine Co., Ltd. Method for treating autoimmune disease by il-17 antagonist
AU2020347952A1 (en) 2019-09-20 2022-04-07 Novartis Ag Methods of treating autoimmune diseases using interleukin-17 (IL-17) antagonists
JP7093940B2 (ja) * 2019-09-25 2022-07-01 国立大学法人 東京大学 全身性強皮症治療用医薬組成物
JP7667142B2 (ja) 2019-09-30 2025-04-22 ヤンセン ファーマシューティカ エヌ．ベー． 大分子モジュレータを用いたｉｌ－１７標的結合アッセイのための組成物及び方法
AU2020386669A1 (en) 2019-11-19 2022-06-02 Novartis Ag Methods of treating Lupus Nephritis using interleukin-17 (IL-17) antagonists
KR20220110512A (ko) 2019-12-06 2022-08-08 노파르티스 아게 인터류킨-17(il-17) 길항제를 사용하여 편평 태선을 치료하는 방법
CN114805577B (zh) * 2019-12-31 2023-11-21 南京融捷康生物科技有限公司 针对il-17ra蛋白的抗体及其制备方法和应用
BR112022026273A2 (pt) 2020-06-23 2023-01-17 Novartis Ag Métodos de tratamento da doença ocular da tireoide e orbitopatia de graves usando antagonistas de interleucina-17 (il-17)
UY39484A (es) 2020-11-02 2022-06-30 Novartis Ag Inhibidores de interleucina-17
IL302569A (en) 2020-11-06 2023-07-01 Novartis Ag Cd19 binding molecules and uses thereof
EP4255927A1 (en) 2020-12-02 2023-10-11 Fresenius Kabi Deutschland GmbH Methods of selectively reducing antibodies
WO2022137132A1 (en) 2020-12-22 2022-06-30 Novartis Ag Methods for reducing the oxidation level of cysteine residues in a secreted recombinantly-expressed protein during cell culture
AU2023262688A1 (en) 2022-04-25 2024-10-24 Novartis Ag Crystalline forms of an il-17 inhibitor
EP4525984A1 (en) 2022-05-16 2025-03-26 Novartis AG Methods of treating giant cell arteritis using interleukin-17 (il-17) antagonists
AU2023270497A1 (en) 2022-05-18 2024-12-05 Novartis Ag Methods of selectively treating tendinopathy using interleukin-17 (il-17) antagonists
EP4406553A1 (en) 2023-01-27 2024-07-31 Fresenius Kabi Deutschland GmbH Stable secukinumab biopharmaceutical composition
WO2024156841A1 (en) 2023-01-27 2024-08-02 Fresenius Kabi Deutschland Gmbh Biopharmaceutical composition
WO2025049345A1 (en) 2023-08-25 2025-03-06 Proteologix Us Inc. Anti-il-13 multispecific antibody constructs and uses thereof
CN117843778B (zh) * 2023-12-21 2024-07-26 北京贝来药业有限公司 针对白介素家族成员的新型纳米抗体及其产品和应用
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
CN119331085B (zh) * 2024-10-16 2025-03-14 中国科学院合肥物质科学研究院 沙贝冠状病毒广谱中和抗体及其应用

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
ATE87659T1 (de) 1986-09-02 1993-04-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
ATE139258T1 (de) 1990-01-12 1996-06-15 Cell Genesys Inc Erzeugung xenogener antikörper
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
DK0546073T3 (da) 1990-08-29 1998-02-02 Genpharm Int Frembringelse og anvendelse af transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
US6274711B1 (en) * 1993-06-14 2001-08-14 Inserm, Institut National De La Sante Et De La Recherche Medicale Purified mammalian CTLA-8 antigens and related reagents
US6562333B1 (en) 1993-06-14 2003-05-13 Schering Corporation Purified mammalian CTLA-8 antigens and related reagents
MX9707021A (es) * 1995-03-23 1997-11-29 Immunex Corp Receptor de il-7.
US6074849A (en) * 1995-07-19 2000-06-13 Genetics Institute, Inc. Polynucleotides encoding human CTLA-8 related proteins
EP0839196B1 (en) * 1995-07-19 2005-05-11 Genetics Institute, LLC Human ctla-8 and uses of ctla-8-related proteins
DK0862454T3 (da) 1995-10-27 2002-12-30 Schering Corp CTLA-8 i kombination med G-CSF eller med G-CSF og IL-6 og anvendelse af CTLA-8 til behandling af infektioner
WO1998023284A1 (en) 1996-11-27 1998-06-04 Immunex Corporation Method of regulating nitric oxide production
US6849719B2 (en) 1997-09-17 2005-02-01 Human Genome Sciences, Inc. Antibody to an IL-17 receptor like protein
US6482923B1 (en) 1997-09-17 2002-11-19 Human Genome Sciences, Inc. Interleukin 17-like receptor protein
AU9482498A (en) 1997-09-17 1999-04-05 Human Genome Sciences, Inc. Interleukin-17 receptor-like protein
AU760035B2 (en) 1997-11-10 2003-05-08 Cytimmune Sciences, Inc. Compositions and methods for targeted delivery of factors
US6562578B1 (en) * 1999-01-11 2003-05-13 Schering Corporation IL-17-like cytokine binding compounds and antibodies
WO1999032632A1 (en) 1997-12-19 1999-07-01 Millennium Pharmaceuticals, Inc. Novel embryo-derived interleukin related factor molecules and uses therefor
EP1045905A2 (en) 1998-01-09 2000-10-25 Immunex Corporation Il-17rh dna and polypeptides
AU2031399A (en) 1998-01-09 1999-07-26 Immunex Corporation Human and murine il-17d, cytokine related to interleukin-17: dna and polypeptides
CA2320626A1 (en) 1998-02-11 1999-08-19 Maxygen, Inc. Genetic vaccine vector engineering
DE69936382T3 (de) 1998-05-15 2011-07-07 Genentech, Inc., Calif. Therapeutische verwendungen von il-17 homologe polypeptide
DK1114156T3 (da) 1998-09-17 2008-03-03 Zymogenetics Inc Transformerende vækstfaktor Beta-9 (ZTGFSS9) fra pattedyr
AU6277799A (en) 1998-10-02 2000-04-26 Eli Lilly And Company Il-17 homolog nucleic acids, polypeptides, vectors, host cells, methods and usesthereof
JP2000186046A (ja) * 1998-10-14 2000-07-04 Snow Brand Milk Prod Co Ltd 慢性関節リウマチ治療剤及び診断方法
AU1071200A (en) 1998-10-19 2000-05-08 Biotech Australia Pty Limited Systems for oral delivery
DE29820466U1 (de) 1998-11-16 1999-04-08 Reutter, Werner, Prof. Dr.med., 14195 Berlin Rekombinante Glycoproteine und sie enthaltende Arzneimittel
US6734172B2 (en) 1998-11-18 2004-05-11 Pacific Northwest Research Institute Surface receptor antigen vaccines
CN1357042A (zh) 1999-01-11 2002-07-03 先灵公司 白介素－17相关哺乳动物细胞因子、编码其的多核苷酸、应用
AR022237A1 (es) 1999-01-11 2002-09-04 Schering Corp Citoquinas mamiferas purificadas; reactivos y metodos relacionados
EP1031346B1 (en) 1999-01-27 2002-05-02 Idea Ag Noninvasive vaccination through the skin
JP4841727B2 (ja) 1999-02-12 2011-12-21 ザ スクリプス リサーチ インスティチュート 抗血管新生治療及び免疫治療の組み合わせを用いる腫瘍及び転移の治療方法
EP1053751A1 (en) * 1999-05-17 2000-11-22 Institut National De La Sante Et De La Recherche Medicale (Inserm) Compositions and methods for treating cell proliferation disorders
US6036128A (en) 1999-05-17 2000-03-14 Common Ground Recycling, Inc. Tire shredding machine and method of using the same
WO2001015728A1 (en) 1999-08-27 2001-03-08 University Health Network Method for activating cytotoxic t-lymphocytes (ctls) in vivo : composition comprising antibody anti cd40 (or cd40l or cd40 binding protein) and an antigen
JP2001086046A (ja) * 1999-09-09 2001-03-30 Nec Corp カメラ付き携帯電話装置
US7220840B2 (en) * 2000-06-16 2007-05-22 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator protein
CN1279055C (zh) 2000-06-16 2006-10-11 人体基因组科学有限公司 免疫特异性结合BLyS的抗体
AU2001296229A1 (en) 2000-10-13 2002-04-29 Eli Lilly And Company Methods of using a human il-17-related polypeptide to treat disease
US6793919B2 (en) * 2000-10-18 2004-09-21 Immunex Corporation Methods for treating rheumatoid arthritis using IL-17 antagonists
ATE501730T1 (de) 2001-01-25 2011-04-15 Zymogenetics Inc Verfahren zur behandlung von psoriasis unter verwendung eines il-17d antagonisten
ATE374214T1 (de) * 2001-04-27 2007-10-15 Kirin Brewery Monoklonaler anti-cd-40-antikörper
CA2467521A1 (en) 2001-11-16 2003-07-10 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to blys
PL376536A1 (pl) 2002-08-28 2006-01-09 Immunex Corporation Kompozycje i sposoby leczenia chorób układu sercowo-naczyniowego
EP1633785B1 (en) * 2003-05-21 2012-11-28 Medarex, Inc. Human monoclonal antibodies against bacillusanthracis protective antigen
CA2544920C (en) 2003-11-21 2012-09-11 Celltech R & D Limited Method for the treatment of multiple sclerosis by inhibiting il-17 activity
BRPI0510617A (pt) 2004-05-03 2007-10-30 Schering Corp uso de expressão de il-17 para prever inflamação de pele; processos de tratamento
GB0417487D0 (en) * 2004-08-05 2004-09-08 Novartis Ag Organic compound
ATE445415T1 (de) 2005-09-01 2009-10-15 Schering Corp Verwendung von il-23 und il-17-antagonisten zur behandlung von autoimmuner entzündlicher augenerkrankung

Also Published As

Publication number Publication date
BE2015C041I2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html) 2024-10-08
NO2022026I1 (no) 2022-06-24
RU2007108067A (ru) 2008-09-10
US20190270804A1 (en) 2019-09-05
IL180717A (en) 2012-07-31
EP2364729A3 (en) 2012-01-18
HUS1800040I1 (hu) 2018-11-28
US20150152178A1 (en) 2015-06-04
CA2573586C (en) 2013-06-25
PT1776142E (pt) 2011-10-06
AR050200A1 (es) 2006-10-04
HUE025815T2 (en) 2016-04-28
DK1776142T3 (da) 2011-10-31
EP2364729B1 (en) 2014-05-14
KR20080029018A (ko) 2008-04-02
PT2364729E (pt) 2014-09-01
CA2573586A1 (en) 2006-02-09
LTPA2015029I1 (lt) 2022-07-11
NO341384B1 (no) 2017-10-30
ATE517924T1 (de) 2011-08-15
PL1776142T4 (pl) 2018-04-30
NL300749I2 (nl) 2017-11-02
TNSN07034A1 (en) 2008-06-02
NO20070985L (no) 2007-03-30
EP1776142B9 (en) 2016-09-07
HRP20181069T1 (hr) 2018-09-07
ES2677245T3 (es) 2018-07-31
EP2902039B1 (en) 2018-04-11
CN101001645A (zh) 2007-07-18
HRP20110758T1 (en) 2011-11-30
CN101001645B (zh) 2012-09-05
AU2010201689B2 (en) 2011-09-29
JP4682200B2 (ja) 2011-05-11
HK1207559A1 (en) 2016-02-05
US20090280131A1 (en) 2009-11-12
PL1776142T3 (pl) 2011-12-30
ES2367440T3 (es) 2011-11-03
DK2902039T3 (en) 2018-07-16
CY2018027I2 (el) 2020-05-29
LU92768I2 (fr) 2015-11-03
US8119131B2 (en) 2012-02-21
NO337129B1 (no) 2016-01-25
CY2015030I1 (el) 2015-11-04
ZA200700242B (en) 2008-08-27
PT2366405E (pt) 2015-06-30
HUE038187T2 (hu) 2018-10-29
ECSP077198A (es) 2007-02-28
NO336279B1 (no) 2015-07-06
US9765140B2 (en) 2017-09-19
LTPA2018515I1 (lt) 2018-10-25
ES2487533T7 (es) 2015-07-14
EP1776142B1 (en) 2011-07-27
RU2426741C2 (ru) 2011-08-20
NO2016017I1 (no) 2016-08-23
SI2366405T1 (sl) 2015-07-31
LUC00088I2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html) 2018-12-17
HRP20110758T4 (hr) 2015-07-31
US20170355762A1 (en) 2017-12-14
HUS1500037I1 (hu) 2017-10-30
US20100215666A1 (en) 2010-08-26
AU2010201689A1 (en) 2010-05-20
US20140079719A1 (en) 2014-03-20
NO348010B1 (no) 2024-06-17
BRPI0513078C1 (pt) 2021-05-25
JP2008507988A (ja) 2008-03-21
EP2366405B1 (en) 2015-02-25
PL1776142T6 (pl) 2016-06-30
SG155186A1 (en) 2009-09-30
CY1115444T1 (el) 2017-01-04
NO2018007I1 (no) 2018-02-14
KR20070036166A (ko) 2007-04-02
EP2364729A2 (en) 2011-09-14
US7807155B2 (en) 2010-10-05
NO20151787L (no) 2006-02-06
WO2006013107A1 (en) 2006-02-09
MY144925A (en) 2011-11-30
GB0417487D0 (en) 2004-09-08
PL2902039T3 (pl) 2018-09-28
ES2367440T9 (es) 2021-04-28
ES2367440T7 (es) 2015-07-14
DK2364729T6 (en) 2015-07-06
DK1776142T6 (en) 2015-07-06
NO2015023I1 (no) 2015-11-02
US20230235038A1 (en) 2023-07-27
NO2015023I2 (no) 2015-10-26
CY1120723T1 (el) 2019-12-11
NZ552658A (en) 2009-11-27
EP2366405A3 (en) 2012-01-18
PL2364729T3 (pl) 2014-10-31
KR100852523B9 (ko) 2025-03-28
EP1776142B3 (en) 2015-06-24
ES2536228T3 (es) 2015-05-21
LT2902039T (lt) 2018-06-25
CY1116256T1 (el) 2017-02-08
CY2015030I2 (el) 2017-11-14
FR15C0048I1 (fr) 2015-08-28
HRP20150480T1 (hr) 2015-07-17
SI2364729T1 (sl) 2014-08-29
CY2018027I1 (el) 2020-05-29
AU2005268857A1 (en) 2006-02-09
DK2366405T3 (en) 2015-05-11
AU2005268857C1 (en) 2012-01-19
BRPI0513078A (pt) 2008-04-22
PT2902039T (pt) 2018-07-17
PE20060418A1 (es) 2006-06-15
BR122018075556B1 (pt) 2022-10-18
EP2902039A1 (en) 2015-08-05
EP1776142A1 (en) 2007-04-25
TW200617025A (en) 2006-06-01
FR15C0048I2 (fr) 2015-11-20
PL2364729T6 (pl) 2016-06-30
TR201808057T4 (tr) 2018-06-21
PL2366405T3 (pl) 2015-08-31
NO20150064L (no) 2007-03-30
SI1776142T1 (sl) 2011-11-30
ES2487533T3 (es) 2014-08-21
SI2902039T1 (en) 2018-07-31
BRPI0513078B8 (pt) 2019-08-27
NO20150065L (no) 2007-03-30
US20120107325A1 (en) 2012-05-03
AU2005268857B2 (en) 2010-01-28
LTC1776142I2 (lt) 2022-07-11
US10344084B2 (en) 2019-07-09
AU2005268857B8 (en) 2010-05-27
EP3409288A1 (en) 2018-12-05
MX2007001338A (es) 2008-03-11
KR100852523B1 (ko) 2008-08-14
NO337286B1 (no) 2016-02-29
EP2364729B3 (en) 2015-06-24
IL180717A0 (en) 2007-06-03
BR122017009404B1 (pt) 2022-02-22
DK2364729T3 (da) 2014-07-21
RU2426741C3 (ru) 2017-11-15
RU2011113153A (ru) 2012-10-20
US8617552B2 (en) 2013-12-31
TWI359153B (en) 2012-03-01
HK1101277A1 (en) 2007-10-12
MA28982B1 (fr) 2007-11-01
US20250122277A1 (en) 2025-04-17
EP2366405A2 (en) 2011-09-21
NO20171697A1 (no) 2007-03-30
HK1256639A1 (en) 2019-09-27
BRPI0513078B1 (pt) 2019-02-19

Similar Documents

Publication Publication Date Title
CY1120723T1 (el) Ανταγωνιστικα αντισωματα il-17
CY1107989T1 (el) Ανασυνδυασμενα αντισωματα της ανθρωπινης ιντepλευκινης-1 βητα
ES2547463T3 (es) Moléculas de unión a ILT3 y usos de las mismas
CY1110033T1 (el) Τεχνητα ανθρωπινα θεραπευτικα αντισωματα εναντια σε ισομορφες cd45
EA201070888A1 (ru) Антитела и их производные
CY1108779T1 (el) Αντισωματα για την ανθρωπινη il-1 βητα
EP1912674A4 (en) BIS SPECIFIC SINGLE CHAIN FV ANTIBODY MOLECULES AND METHOD OF USE THEREOF
CY1115871T1 (el) Μεθοδοι για την αντιμετωπιση ουρικης αρθριτιδας
ATE492563T1 (de) Vollständige humane monoklonale antikörper gegen il-13
ATE476994T1 (de) Antikörper gegen gpnmb und ihre verwendungen
RS53318B (en) B-CELL REDUCTION BY USING CD37-SPECIFIC AND CD20-SPECIFIC BINDING MOLECULES
EA200900040A1 (ru) Молекулы антител, которые связываются с человеческим il-17
CR8698A (es) Anticuerpos monoclonales al factor de crecimiento de hepatocito
NZ594682A (en) Fully human antibodies specific to cadm1
DK2109623T3 (da) Cancerbehandling med anti-IL-1-antistoffer
RU2011142183A (ru) Средство для лечения ревматоидного артрита
EA200700876A1 (ru) Агенты, специфически связывающие ангиопоэтин-2
ATE478707T1 (de) Kim-1-antikörper zur behandlung von th2- vermittelten erkrankungen
TH55112B (th) แอนติบอดีของ il-17 แอนติโกนิสติก
TH114402A (th) แอนติบอดีของ il-17 แอนติโกนิสติก
UA108734C2 (uk) Моноклональне антитіло, що специфічно зв'язується з протеїнконвертазою субтілізин кексин типу 9 (pcsk9)
EA200701031A1 (ru) Молекулы, способствующие гематопоэзу
EA202190387A1 (ru) Антитело к cd38 человека и его применение
CY1115000T1 (el) Ανθρωπινα αντισωματα εναντια στη λυσσα και χρησεις αυτων
TH71073A (th) แอนติบอดีโมเลกุลที่มีความจำเพาะสำหรับ il-1(เบตา) ของคน